Rodrigo De Almeida Toledo

Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

Encorafenib plus cetuximab is a standard option in the treatment of BRAFV600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A ...

Guglielmo Vetere ;

G. Fontanini ;

Rodrigo De Almeida Toledo ;

F. Bergamo ;

Giovanni Randon , MD;

Simone Oldani ;

Walter Ferrari Bravo ;

Gianmarco Ricagno ;

Paola Vignali ;

Sara Lonardi ;

E. Elez ;

R. Moretto ;

M. Germani ;

M. Giordano ;

Rossana Intini ;

C. Cremolini ;

Filippo Ghelardi ;

C. Ugolini ;

06/25/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Rodrigo De Almeida Toledo

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products